Read More

Bristol Myers Squibb Provides Update On RELATIVITY-123 Trial Evaluating The Fixed-Dose Combination Of Nivolumab And Relatlimab In Patients With Previously Treated Metastatic Microsatellite Stable Colorectal Cancer

Bristol Myers Squibb (NYSE:BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic

BMY

Read More

Axalta Named Exclusive Supplier For BMW Group’s Private Paint Label ColorSystem In EMEA; Adds To Existing Supplier Agreements; Up To 45% Reduction In Carbon Equivalent Emissions Across 730 Franchised Dealer Collision Repair Shops

Adds to existing supplier agreements   Up to 45% reduction in carbon equivalent emissions across 730 franchised dealer collision repair shops GLEN MILLS, Pa., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Axalta

AXTA